TREATMENT MONITORING

hPG80:

A Biomarker to Monitor Treatment Response

In clinical practice, rapid assessment of treatment efficacy is a laudable goal. Dynamic shifts in the biomarker during treatment indicate that the current therapy is effectively reducing tumor burden or slowing cancer progression.

hPG80 Longitudinal Changes Related to Treatment Efficacy and Cancer Activity

Using a retrospective cohort of 84 hepatocellular carcinoma patients, we analyzed the longitudinal changes in hPG80 and AFP concentrations during the treatment management.

In these two typical patients, hPG80, initially present before the treatment, became undetectable following the patient’s complete response. At progression, hPG80 becomes detectable again. This increase was detectable before the relapse for patient #1. AFP was not informative due to its low concentration below the 20 ng/ml cut-off for patient #2.

Patient #1

Adapted from You et al. EBioMedicine, 2020, data on file.

Patient #2